You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 166 No. 5, March 13, 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Psychiatry
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Atypical Antipsychotics Have Very Different Adverse Effect Profiles and Should Not Be Lumped Together

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

While the work of Rochon et al1 is laudable in intent, it is, unfortunately, misleading in its title and in its conclusions, although clearly stating the authors' caveats about these very conclusions. The authors made the same mistake the Food and Drug Administration made in categorizing the atypical antipsychotic drugs as a single class. In this study, 80% of their patients were initially dispensed risperidone; 18%, olanzapine; and 2%, quetiapine fumarate. While these drugs are all labeled "atypical," there is no consensus definition of what "atypical" means. These drugs have very different movement disorder adverse effects. Data from a study on Parkinson disease (PD) suggest that quetiapine does not worsen motor function, whereas olanzapine and risperidone do.2 Because all the dementing illnesses are associated with parkinsonism, the effects of these drugs in PD is relevant.3 A recent placebo-controlled trial, in fact, confirms this.4 In the nonelderly, risperidone has been associated . . . [Full Text of this Article]


AUTHOR INFORMATION
Joseph H. Friedman, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Atypical Antipsychotics Have Very Different Adverse Effect Profiles and Should Not Be Lumped Together—Reply
Sudeep Gill, Connie Marras, Geoffrey M. Anderson, Philip E. Lee, Jerry H. Gurwitz, and Paula A. Rochon
Arch Intern Med. 2006;166(5):586-587.
EXTRACT | FULL TEXT  

Atypical Antipsychotics and Parkinsonism
Paula A. Rochon, Therese A. Stukel, Kathy Sykora, Sudeep Gill, Susan Garfinkel, Geoffrey M. Anderson, Sharon-Lise T. Normand, Muhammad Mamdani, Philip E. Lee, Ping Li, Susan E. Bronskill, Connie Marras, and Jerry H. Gurwitz
Arch Intern Med. 2005;165(16):1882-1888.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.